ABORDAGEM DO SÍNDROME HEPATORRENAL NO DOENTE CRÍTICO | HEPATORENAL SYNDROME MANAGEMENT IN THE INTENSIVE CARE UNIT
Resumo
PT | RESUMO
O síndrome hepatorrenal é uma forma de lesão renal funcional num doente com evidência de doença hepática grave,
com hipertensão portal. O diagnóstico é clínico e baseado em determinados critérios estabelecidos, sendo geralmente tardio,
porque exige a exclusão de outras causas de disfunção renal. O tratamento ideal passa pela resolução parcial da doença
primária ou do sucesso do transplante hepático, que permanece como terapêutica chave. Os vasoconstritores sistémicos e a
albumina podem ser usados como ponte para o transplante ou como tratamento alternativo, caso o doente não seja candidato
a transplante hepático.
Os autores apresentam uma revisão da abordagem do síndrome hepatorrenal no doente crítico. A pesquisa bibliográfica
foi realizada através de ferramentas eletrónicas de pesquisa avançada e não avançada da fonte de dados PubMed. Os artigos
citados foram considerados os mais relevantes.
Palavras-chave: Síndrome hepatorrenal; Unidade de cuidados intensivos
EN | ABSTRACT
Hepatorenal syndrome is a form of functional kidney injury in a patient with evidence of severe liver disease with portal hypertension.
The diagnosis is clinical and based on certain established criteria, being generally late because it requires the exclusion of other causes of
renal impairment. The ideal treatment is either to resolve the primary disease or to rely on the success of liver transplant, which remains the
key treatment. Systemic vasoconstrictors and albumin may be used as a bridge for the liver transplant or as an alternative management if the
patient is not a candidate for it.
The authors present a review of the hepatorenal syndrome management in critically ill patients. A bibliographic review was performed by
using advanced and not advanced electronic research tools from the PubMed data source. The cited articles were considered the most relevant.
Keywords: Hepatorenal syndrome; Intensive care unit
Texto Completo:
PDFReferências
Ginès P, Schrier RW. Renal Failure in Cirrhosis. N Engl J Med. 2009;361:1279-90.
Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet. 2003;362:1819-27.
Better OS. Renal and cardiovascular dysfunction in liver disease. Kidney Int. 1986;29:598-607.
Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal
syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164-76.
Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis:
Revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968-74.
Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310-8.
Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56:S1-S12.
European Association for the Study of the Liver. EASL clinical pratice guidelines on the management of ascitis, spontaneous bacterial peritonitis,
and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397-417.
Alexopoulou A, Agiasotelli D, Vasilieva LE, Dourakis SP. Bacterial translocation markers in liver cirrhosis. Ann Gastroenterol. 2017;30:486-97.
Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz L, et al. Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients
with Cirrhosis and Spontaneous Bacterial Peritonitis. N Engl J Med. 1999;341:403-9.
Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, et al. Renal failure and bacterial infections in patients with cirrhosis: Epidemiology
and clinical features. Hepatology. 2007;45:223-9.
Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac E, et al. Model for end-stage liver disease score and systemic inflammatory
response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology. 2007;46:1872-82.
Barreto R, Fagundes C, Guevara M, Solà E, Pereira G, Rodríguez E, et al. Type-1 hepatorenal syndrome associated with infections in cirrhosis.
Natural history, outcome of kidney function and survival. Hepatology. 2014;59:1505-13.
Wu C-C, Yeung L-K, Tsai W-S, Tseng CF, Chu P, Huang TY, et al. Incidence and factors predictive of acute renal failure in patients with advanced
liver cirrhosis. Clin Nephrol. 2006;65:28-33.
Wong F; Leung W; Al Beshir M, Marquez, M; Renner E. Outcomes of Patients With Cirrhosis and Hepatorenal Syndrome Type 1 Treated With
Liver Transplantation. Liver Transplant. 2015;21:300-7.
Veldt BJ, Lainé F, Guillygomarc’h A, Lauvin L, Boudjema K, Messner M, et al. Indication of liver transplantation in severe alcoholic liver
cirrhosis: quantitative evaluation and optimal timing. J Hepatol. 2002;36:93-8.
Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis
resulting from chronic hepatitis B. Hepatology. 2000;31:207-10.
Keller F, Heinze H, Jochimsen F, Passfall J, Schuppan D, Buttner. Risk factors and outcome of 107 patients with decompensated liver disease
and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail. 1995;17:135–46.
Capling, RK; Bastani B. The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren Fail. 2004;26:563-8.
Charlton MR, Wall WJ, Ojo AO, Ginès P, Textor S, Shihab FS, et al. Report of the First International Liver Transplantation Society Expert Panel
Consensus Conference on Renal Insufficiency in Liver Transplantation. Liver Transplant. 2009;15:S1-S34.
Restuccia T, Ortega R, Guevara M, Ginès P, Alessandria C, Ozdogan O, et al. Effects of treatment of hepatorenal syndrome before transplantation
on posttransplantation outcome. A case-control study. J Hepatol. 2004;40:140-6.
Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmerón JM, Jiménez W, et al. Reversibility of hepatorenal syndrome by prolonged
administration of ornipressin and plasma volume expansion. Hepatology. 1998;27:35-41.
Sanyal AJ, Boyer T, Garcia–Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A Randomized, Prospective, Double-Blind, Placebo-Controlled
Trial of Terlipressin for Type 1 Hepatorenal Syndrome. Gastroenterology. 2008;134:1360-8.
Martín–Llahí M, Pépin M, Guevara M, Díaz F, Torre A, Monescillo A, et al. Terlipressin and Albumin vs Albumin in Patients With Cirrhosis and
Hepatorenal Syndrome: A Randomized Study. Gastroenterology. 2008;134:1352-9.
Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin
in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015;62:567-74.
Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: Type 1 HRS and beyond. Hepatology. 2006;43:385-94.
Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome
(HRS) type 1: Relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55:315-21.
Duvoux C, Zanditenas D, Hézode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type
I hepatorenal syndrome: a pilot study. Hepatology. 2002;36:374-80.
Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: A
randomized study. J Hepatol. 2012;56:1293-8.
Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, Heras D, et al. Terlipressin therapy with and without albumin for patients with hepatorenal
syndrome: Results of a prospective, nonrandomized study. Hepatology. 2002;36:941-8.
Guevara M, Ginès P, Bandi JC,Gilabert R, Sort P, Jimenéz W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome:
effects on renal function and vasoactive systems. Hepatology. 1998;28:41622
Malinchoc M, Kamath PS, Gordon FD, Peine C, Rank J, ter Borg PCJ. A model to predict poor survival in patients undergoing transjugular
intrahepatic portosystemic shunts. Hepatology. 2000;31:864-71.
Carreiro Ge;; Moreira A MuradFF Azevedo F; Coelho HS. TIPS - ANASTOMOSE PORTOSSISTÊMICA INTRA-HEPÁTICA TRANSJUGULAR.
Revisão. Arq Gatroenterol. 2001;38:69-80.
Rössle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut.
;59:988-1000.
Witzke O, Baumann M, Patschan D, Mitchell A, Treichel V, Gerken G, et al. Which patients benefit from hemodialysis therapy in hepatorenal
syndrome? J Gastroenterol Hepatol. 2004;19:1369-73.
Stanley MM, Ochi S, Lee KK, Nemchausky BA, Greenlee HB, Allen JI, et al. Peritoneovenous Shunting as Compared with Medical Treatment
in Patients with Alcoholic Cirrhosis and Massive Ascites. N Engl J Med. 1989;321:1632-38.
Stauber, R; Krisper P. MARS and Prometheus in Acute-on-Chronic Liver Failure: Toxin Elimination and Outcome. Transplantationsmedizin.
;22:333-38.
Laffi G, Daskalopoulos G, Kronborg I, Hsueh W, Gentilini P, Zipser RD. Effects of sulindac and ibuprofen in patients with cirrhosis and ascites.
An explanation for the renal-sparing effect of sulindac. Gastroenterology. 1986;90:182-87.
Briglia AE, Anania FA. Hepatorenal syndrome. Definition, pathophysiology, and intervention. Crit Care Clin. 2002;18:345-73.
Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of
randomized trials. Clin Gastroenterol Hepatol. 2013;11:123-30.
Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jiménez W, Arroyo V, et al. MELD score and clinical type predict prognosis in hepatorenal
syndrome: Relevance to liver transplantation. Hepatology. 2005;41:1282-89.
Cassinello C, Moreno E, Gozalo A, Ortuno B, Cuenca B, Solis-Herruzo JA. Effects of orthotopic liver transplantation on vasoactive systems and
renal function in patients with advanced liver cirrhosis. Dig Dis Sci. 2003;48:179-86.
Gines A, Escorsell A, Gines P, Saló J, Jiménez W, Inglada L et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in
cirrhosis with ascites. Gastroenterology. 1993;105:229-36.
Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G et al. Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays
Hepatorenal Syndrome and Improves Survival in Cirrhosis. Gastroenterology. 2007;133:818-24.
Tyagi P, Sharma P, Sharma BC, Puri AS, Kumar A, Sarin SK. Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot
randomized control trial between pentoxifylline and placebo. Eur J Gastroenterol Hepatol. 2011;23:210.
Mucino-Bermejo J, Carrillo-Esper R, Uribe M, Mendez-Sanchez N. Acute kidney injury in critically ill cirrhotic patients: a review. Ann Hepatol.
;11:301-10.
Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane database Syst Rev. October 2009:CD007339.
Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a
double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637-48.
Apontamentos
- Não há apontamentos.